N-Telopeptide, Cross-Linked, Urine
Ordering Recommendation
New York DOH Approval Status
Specimen Required
For monitoring therapy, a baseline specimen should be collected prior to initiation of therapy. Subsequent specimens for comparison should be collected at the same time of day as the baseline specimen.
Second-morning void or 24-hour urine. Refrigerate during collection. Collect without preservative.
Transfer a 1 mL aliquot of urine from a well-mixed, second-morning void or 24-hour collection to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Frozen.
Specimens contaminated with blood or extensive hemolysis.
Ambient: 24 hours; Refrigerated: 1 week; Frozen: 4 weeks
Methodology
Quantitative Chemiluminescent Immunoassay (CLIA)
Performed
Tue-Sat
Reported
1-4 days
Reference Interval
Age |
Male |
Female |
---|---|---|
7-9 years | 167-578 nM BCE/mM creatinine | 201-626 nM BCE/mM creatinine |
10-12 years | 152-505 nM BCE/mM creatinine | 173-728 nM BCE/mM creatinine |
13-15 years | 103-776 nM BCE/mM creatinine | 38-515 nM BCE/mM creatinine |
16-17 years | 34-313 nM BCE/mM creatinine | 20-144 nM BCE/mM creatinine |
18 years and older | 21-83 nM BCE/mM creatinine | |
Premenopausal | 17-94 nM BCE/mM creatinine | |
Postmenopausal | 26-124 nM BCE/mM creatinine |
Interpretive Data
NTx Units = nM BCE/mM creatinine
A decrease of 30-40% from the NTx baseline after three months of therapy is a typical response to anti-resorptive therapy.
NTx = Cross-linked N-telopeptide of Type I Collagen
BCE = Bone Collagen Equivalent
FDA
Note
Hotline History
Hotline History
CPT Codes
82523
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0020207 | Creatinine, Urine - per volume | 2161-8 |
0070061 | NTx, Urine (nM BCE/mM Creatinine) | 14115-0 |
Aliases
- Collagen Crosslinks
- Cross-Linked N-Telopeptide
- Crosslinked N-telopeptide of Type I Collagen
- N-Telopeptide, Urine
- NTx
- NTX Creatinine
- NTX Urine
- Osteomark
- Osteoporosis